Fibrocell has finished a proof-of-concept trial on FCX-013 for the treatment of linear scleroderma. The trial examined the efficacy of FCX-013 in reducing dermal thickness in fibrotic tissue. Scleroderma News Today, 02/09/2016. (Also see: Linear Scleroderma Treatments)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.